Enliven Therapeutics, Inc. (ELVN)
$39.28-0.53%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.8B
- Beta
- 0.24
- P/E (TTM)
- -23.95
- Short % float
- 22.70%
- Days to cover
- 5.5
- SI change
- +20.1%
- 1W
- -5.03%
- 1M
- -26.39%
- vs SPY 1W
- -4.05%
- vs SPY 1M
- -28.25%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$40.1BRECOVERYQ 30$188.44+2.70%
- INCYSELLIncyte Corporation$22.0BBEARQ 13$108.62+2.72%
- EXELBUYExelixis, Inc.$15.0BBULLQ 10$59.51+2.49%
- RLAYSELLRelay Therapeutics, Inc.$3.8BRECOVERYQ 2$17.36-1.73%
- NUVBSELLNuvation Bio Inc.$1.6BCRISISQ 4$4.72-0.85%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.2BCRISISQ 15$13.95-3.01%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.31+2.48%
- TYRASELLTyra Biosciences, Inc.$1.1BCRISISQ 5$18.56+0.75%
- CGEMSELLCullinan Therapeutics, Inc.$867MCRISISQ 0$14.10-3.26%
- AVBPSELLArriVent BioPharma, Inc.$749MCRISISQ -6$16.09+0.68%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ELVN?
- LOPJLB’s latest quantitative signal on Enliven Therapeutics, Inc. (ELVN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ELVN in?
- Enliven Therapeutics, Inc. (ELVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Enliven Therapeutics, Inc. (ELVN) do?
- Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, als…